Peroxisome proliferator-activated receptor γ (PPARγ), a nuclear receptor and transcription
factor that regulates the expression of many genes relevant to carcinogenesis, is now an …

Breast cancer remains a worldwide public health concern despite the fact that mortality rates
have been declining in some countries as a result of improvements in adjuvant therapy and …

Abstract Arzoxifene ([6-hydroxy-3-[4-[2-(1-piperidinyl)-ethoxy] phenoxy]-2-(4-
methoxyphenyl)] benzo [b] thiophene) is a selective estrogen receptor modulator (SERM) …

PURPOSE: To test the hypothesis that risk factors related to lifetime estrogen exposure
predict breast cancer incidence and to test if any subgroups experience enhanced benefit …

Tamoxifen is one of the most effective treatments for breast cancer through its ability to
antagonize estrogendependent growth by binding estrogen receptors (ERs) and inhibiting …

The agents used for endocrine therapy in patients with breast cancer have changed
markedly over the past decade. Tamoxifen remains the anti-oestrogen of choice, but could …

The effect on the IGF system of 60 mg and 600 mg daily of raloxifene administered for 2
weeks prior to surgery was investigated in 37 postmenopausal women with breast cancer …

Raloxifene, a selective estrogen receptor modulator (SERM), was designed to have the
expected benefits of long‐term estrogen replacement therapy without the risks. This paper …

L'ostéoporose est un problème majeur de santé publique. On observe chaque année en
France 50 000 à 150000 nouveaux cas de fractures vertébrales et 50 000 fractures de …

Raloxifene is a member of a family of drugs known as selective estrogen receptor
modulators (SERMs). Raloxifene is currently approved by the FDA for the prevention and …